MetaCap

CAMP4 Therapeutics (CAMP) vs Enanta Pharmaceuticals (ENTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CAMP4 Therapeutics (CAMP) has outperformed Enanta Pharmaceuticals (ENTA) over the past year, gaining 30.7% versus a loss of 40.1%. CAMP4 Therapeutics is the larger company by market cap ($237.8 million vs $222.2 million), about 1.1 times the size. Enanta Pharmaceuticals converts more of its revenue into profit, with a net margin of -108.3% versus -2298.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAMP+30.69%ENTA-40.14%
+155%+53%-49%
Nov 21, 20251 yearNov 20, 2026
CAMP-64.65%ENTA-30.98%
+60%-17%-94%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAMP versus ENTA key metrics
MetricCAMPENTA
Share price$3.79$7.62
Market cap$237.84M$222.19M
1-day change-5.25%-4.51%
YTD return-38.17%-51.68%
1-year return+30.69%-40.14%
5-year return—-91.71%
EPS (TTM)$-2.11$-2.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.50M$63.00M
Revenue growth (YoY)+436.50%-3.56%
Net income (latest FY)$-80.40M$-68.25M
Operating margin-1502.43%-99.01%
Net margin-2298.54%-108.33%
52-week high$7.75$17.15
52-week low$2.90$7.56
Distance from 52-week high-51.10%-55.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+169.66%+186.48%
Average volume238.88K287.81K
Shares outstanding62.75M29.16M
Employees48120
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAMP has outperformed ENTA by 70.8 percentage points over the past year.
  • Enanta Pharmaceuticals is more profitable, keeping -108.3 cents of every revenue dollar as net income versus -2298.5 cents for CAMP4 Therapeutics.
  • CAMP4 Therapeutics grew revenue faster in its latest fiscal year (+436.50% vs -3.56%).

About CAMP4 Therapeutics

CAMP stock →

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About Enanta Pharmaceuticals

ENTA stock →

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees

CAMP vs ENTA FAQ

Which is bigger, CAMP4 Therapeutics or Enanta Pharmaceuticals?

CAMP4 Therapeutics (CAMP) is larger, with a market capitalization of $237.84M compared with $222.19M for Enanta Pharmaceuticals (ENTA).

Which stock has performed better over the past year, CAMP or ENTA?

CAMP returned +30.69% over the past 12 months, compared with -40.14% for ENTA (price return, excluding dividends). Past performance does not predict future results.

Are CAMP4 Therapeutics and Enanta Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons